Date: December 3, 2018 (Monday)
Time: 9:00 a.m. – 6:00 p.m.
Venue: Rayson Huang Theatre, The University of Hong Kong, Pokfulam Road, Hong Kong
Co-organized by
Dr. Li Dak-Sum Research Centre, The University of Hong Kong
Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Hong Kong
Dr. Li Dak-Sum Research Centre, the University of Hong Kong and Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Hong Kong are pleased to invite friends, colleagues and students in the fields of regenerative medicine, cardiology and bioengineering to join our symposium on heart regeneration.
This year’s symposium will feature a full day program where scientists from academia and industry around the world will meet and deliver talks on important themes within the scope of regenerative medicine, precision medicine and novel drug discovery.
The symposium will cover a broad range of topics in the field of cardiac regenerative medicine, ranging from novel model systems to unravel human heart diseases, regenerative cardiology, modeling of cardiovascular diseases with stem cell-based models, to novel bioengineering technologies, bioartificial heart tissues and translational bench to bedside regenerative medicine.
Programme Rundown
08:30
REGISTRATION
09:00
WELCOME AND OPENING REMARKS
Session I: Cell-Based Cardiac Therapies
09:15 – 09:45
Gene therapy & genome editing for acquired and experimental heart failure
Roger Hajjar
Director, Cardiovascular Research Center
Arthur & Janet C. Ross Professor of Medicine, Icahn School of Medicine at Mount Sinai
09:45 – 10:15
The potential of human induced pluripotent stem cells to model and to treat congenital heart disease
Yiu-fai Cheung
Bryan Lin Professor in Paediatric Cardiology
Clinical Professor
Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong
10:15 – 10:45
Development of banking and testing protocols for GMP hiPSC
Jo Mountford
Head of Cellular Therapeutics, Tissues Cells and Advanced Therapies, Scottish National Blood Transfusion Service
Hon. Associate Professor, Institute of Cardiovascular and Medical Sciences, University of Glasgow
10:45 – 11:15
Predicting individual arrhythmogenic risk at the individual level using hiPSC
Jean-Sébastien Hulot
Team Leader, Clinical & Translational Investigation Center, Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest)
Paris Cardiovascular Research Center PARCC / INSERM
11:15 – 11:30
COFFEE BREAK
Session II: Tissue Engineering and Drug Discovery
11:30 – 12:00
Engineering cardiac tissue and development
Peter Zandstra
Director, School of Biomedical Engineering, The University of British Columbia
12:00 – 12:30
A tissue-engineered scale model of the heart ventricle
Luke MacQueen/Kit Parker
Postdoctoral Fellow/Professor
Bioengineering in the Wyss Institute, Harvard University
12:30 – 13:00
Small molecule drug discovery, transitioning from industry to academia:
SERCA2a SUMO activators for heart failure
Robert DeVita
Director of Medicinal Chemistry, Drug Discovery Institute
Professor, Department of Pharmacological Sciences
Icahn School of Medicine at Mt. Sinai, New York, NY
13:00 – 14:30
LUNCH
Session III: Drug and Therapeutics Safety and Discovery in Industry
14:30 – 15:00
Stem cell cardiomyocytes in drug discovery and development - are we there yet?
Bernard Fermini
Co-Chair, CiPA Ion Channel Working Group of the U.S. Food and Drug Administration
15:00 – 15:30
New challenges in safety pharmacology
Sonja Stoelzle-Feix
Director Scientific Affairs at Nanion Technologies
Co-chair of the CiPA Ion Channel Working Group
15:30 – 16:00
Toward a precision medicine approach to drug screening using Novoheart’s hPSC-based MyHeartTM Platform
Kevin Costa
Co-funder and Chief Scientific Officer, Novoheart
16:00 – 16:30
Collaborating to create engineered human tissues using 3D bioprinting technology
Tamer Mohamed
President and Chief Executive Officer, Aspect Biosystems
16:30 – 16:45
COFFEE BREAK
Session IV: Commercializing Regenerative Medicine and Therapeutics
16:45 – 17:15
Scale-up of pluripotent stem cell production to enable translation and commercialization
Emily Titus
Vice President. Technology Advancement, Centre for Commercialization of Regenerative Medicine (CCRM)
17:15 – 17:45
Where is Hong Kong in developing precision medicine?
Sabrina Chan
Senior Executive Director, The Hong Kong Association of the Pharmaceutical Industry
17:45 – 18:00
CLOSING REMARKS
Registration and Enquiries
Registration is free. Please click the following link for online registration: https://hkuems1.hku.hk/hkuems/ec_hdetail.aspx?guest=Y&ueid=59425
For enquiries, please contact Dr. Thomas Leon at tleon@hku.hk.
CME points would be granted for local participants.
ความคิดเห็น